Literature DB >> 12955286

Cognition in schizophrenia: from basic science to clinical treatment.

Philip D Harvey1, Mark A Geyer, Trevor W Robbins, John H Krystal.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12955286     DOI： 10.1007/s00213-003-1581-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  4 in total

1.  Medicine. What are the right targets for psychopharmacology?

Authors:  Steven E Hyman; Wayne S Fenton
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

Review 2.  Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

Authors:  M F Green; R S Kern; D L Braff; J Mintz
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

3.  Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.

Authors:  P D Harvey; E Howanitz; M Parrella; L White; M Davidson; R C Mohs; J Hoblyn; K L Davis
Journal:  Am J Psychiatry       Date:  1998-08       Impact factor: 18.112

Review 4.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112
  4 in total
  9 in total

Review 1.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

2.  Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Yang Zhang; Da Chun Chen; Mei Hong Xiu; Colin N Haile; Xingguang Luo; Ke Xu; Hui Ping Zhang; Lingjun Zuo; Zhijun Zhang; Xiangrong Zhang; Therese A Kosten; Thomas R Kosten
Journal:  Hum Genet       Date:  2012-02-24       Impact factor: 4.132

3.  The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.

Authors:  Donnie Eddins; Terence G Hamill; Vanita Puri; Christopher E Cannon; Jeffrey A Vivian; Sandra M Sanabria-Bohórquez; Jacquelynn J Cook; John A Morrow; Fiona Thomson; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2013-09-20       Impact factor: 4.530

4.  Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Authors:  Ikwunga Wonodi; Robert P McMahon; Nithin Krishna; Braxton D Mitchell; Judy Liu; Matthew Glassman; L Elliot Hong; James M Gold
Journal:  Schizophr Res       Date:  2014-11-14       Impact factor: 4.939

5.  Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions.

Authors:  David S Tait; Hugh M Marston; Mohammed Shahid; Verity J Brown
Journal:  Psychopharmacology (Berl)       Date:  2008-10-17       Impact factor: 4.530

6.  Functional neuroimaging of schizophrenia: from a genetic predisposition to the emergence of symptoms.

Authors:  Paul C Fletcher
Journal:  Brain       Date:  2004-03       Impact factor: 13.501

Review 7.  A review of the effects of modafinil on cognition in schizophrenia.

Authors:  Sharon Morein-Zamir; Danielle C Turner; Barbara J Sahakian
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

8.  Association between decreased serum TBIL concentration and immediate memory impairment in schizophrenia patients.

Authors:  Xiao Li Yin; Qiu Fang Jia; Guang Ya Zhang; Jian Ping Zhang; Tomoaki Shirao; Cai Xia Jiang; Xu Yuan Yin; Yan Song Liu; Peng Chen; Xiao Chu Gu; Zheng Kang Qian; Guang Zhong Yin; Hai Sen Xia; Li Hui
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

9.  Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action.

Authors:  Xingqin Zhou; Gangming Cai; Shishi Mao; Dong Xu; Xijie Xu; Rongjun Zhang; Zhiwen Yao
Journal:  BMC Psychiatry       Date:  2020-03-06       Impact factor: 3.630
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.